{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T16:32:03Z","timestamp":1720801923307},"reference-count":51,"publisher":"Elsevier BV","issue":"3-4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejps.2013.07.012","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T17:17:56Z","timestamp":1375291076000},"page":"290-302","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human"],"prefix":"10.1016","volume":"50","author":[{"given":"Jian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.07.012_b0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0731-7085(91)80246-6","article-title":"Solubility and acid-base behavior of midazolam in media of different pH, studied by ultraviolet spectrophotometry with multicomponent software","volume":"9","author":"Andersin","year":"1991","journal-title":"J. Pharm. Bio. Ana."},{"key":"10.1016\/j.ejps.2013.07.012_b0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2125.1994.tb04266.x","article-title":"Dose of midazolam should be reduced during diltiazem and verapamil treatments","volume":"37","author":"Backman","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0020","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/jps.21572","article-title":"Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption","volume":"98","author":"Badhan","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2013.07.012_b0025","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF00168924","article-title":"Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans","volume":"353","author":"Busse","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/chir.530050609","article-title":"Stereospecific determination of the in vitro dissolution of modified release formulations of (\u00b1)-verapamil","volume":"5","author":"Carr","year":"1993","journal-title":"Chirality"},{"key":"10.1016\/j.ejps.2013.07.012_b0035","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1124\/dmd.111.040634","article-title":"Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug\u2013drug interaction","volume":"39","author":"Chen","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0040","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1124\/dmd.105.008730","article-title":"Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole","volume":"34","author":"Chien","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0045","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1984.tb02371.x","article-title":"Pharmacokinetics of (+)-, (\u2212) - and (\u00b1)-verapamil after intravenous administration","volume":"17","author":"Eichelbaum","year":"1984","journal-title":"Br. J. Clin. Pharmac."},{"key":"10.1016\/j.ejps.2013.07.012_b0050","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jps.21802","article-title":"Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates","volume":"99","author":"Fenneteau","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0055","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1124\/dmd.110.032649","article-title":"Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data","volume":"38","author":"Gertz","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0060","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction","author":"Gertz","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/dmd.107.018713","article-title":"Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations","volume":"36","author":"Gertz","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0075","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0080","first-page":"371","article-title":"Determination of simvastatin in pharmaceutical dosage forms by optimized and validated method using HPLC\/UV","volume":"83","author":"Guzik","year":"2010","journal-title":"Croat. Chem. Acta."},{"key":"10.1016\/j.ejps.2013.07.012_b0085","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s002280000189","article-title":"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers","volume":"56","author":"Ho","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0090","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/00498250600683197","article-title":"Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability","volume":"36","author":"Howgate","year":"2006","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejps.2013.07.012_b0095","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/dmd.31.7.945","article-title":"Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes","volume":"31","author":"Ito","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0100","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin and atorvastatin when coadministered with cytochrome P450 inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejps.2013.07.012_b0105","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2125.1995.tb04492.x","article-title":"Influence of metabolites on protein binding of verapamil enantiomers","volume":"39","author":"Johnson","year":"1995","journal-title":"Br. J. Clin. Pharmac."},{"key":"10.1016\/j.ejps.2013.07.012_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0009-9236(98)90151-5","article-title":"Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations","volume":"64","author":"Kantola","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0009-9236(95)90195-7","article-title":"Verapamil stereoisomerism: enantiomeric ratio is plasma dependent on peak concentrations, oral input rate or both","volume":"58","author":"Karim","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0120","first-page":"1052","article-title":"Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects","volume":"260","author":"Kroemer","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.clpt.2005.11.001","article-title":"The effect of short- and long-term administration of verapamil on the disposition of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates","volume":"79","author":"Lemma","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0130","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0378-5173(96)04487-0","article-title":"Evaluation of stereoselective dissolution of verapamil hydrochloride from matrix tablets press-coated with chiral excipients","volume":"136","author":"Maggi","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.07.012_b0135","first-page":"1042","article-title":"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action","volume":"253","author":"Mikus","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0140","first-page":"1350","article-title":"Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes","volume":"27","author":"Obach","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0145","first-page":"1552","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0150","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/11318130-000000000-00000","article-title":"Predictions of metabolic drug\u2013drug interactions using physiologically based modeling-two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil","volume":"49","author":"Perdaems","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2013.07.012_b0155","first-page":"618","article-title":"Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms","volume":"292","author":"Perloff","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0160","first-page":"1","article-title":"PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach","author":"Poulin","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0165","first-page":"126","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<577::AID-BDD984>3.0.CO;2-P","article-title":"Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding","volume":"17","author":"Robinson","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0175","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2125.1988.tb03321.x","article-title":"Cyclosporin\u2013verapamil interaction","volume":"25","author":"Roboson","year":"1988","journal-title":"Br. J. Clin. Pharmac."},{"key":"10.1016\/j.ejps.2013.07.012_b0180","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.20322","article-title":"Physiologically based pharmacokinetic modeling 1: Predicting the tissue distribution of moderate-to-strong bases","volume":"94","author":"Rodgers","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0185","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.07.012_b0190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"Rowland-Yeo","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0195","unstructured":"Rowland-Yeo, K., Rostami-Hodjegan, A., and Tucker, G.T., 2003. Abundance of cytochrome P450 in human liver: a meta-analysis. British Pharmacological Society winter meeting, university of London."},{"key":"10.1016\/j.ejps.2013.07.012_b0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A drug\u2013drug interactions by physiologically based pharmacokinetic modeling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland-Yeo","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0205","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1023\/A:1011916329863","article-title":"Jejunal absorption and metabolism of R\/S-verapamil in humans","volume":"15","author":"Sandstr\u00f6m","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.07.012_b0210","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1046\/j.1365-2125.1996.35717.x","article-title":"Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation","volume":"41","author":"Schmider","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/clpt.1981.223","article-title":"Reduced verapamil clearance during long-term oral administration","volume":"30","author":"Shand","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.012_b0220","first-page":"582","article-title":"Dose-dependent pharmacokinetics of cyclosporine A in rats: events in tissues","volume":"28","author":"Tanaka","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0225","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1046\/j.1365-2125.1999.00923.x","article-title":"Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil","volume":"47","author":"Tracy","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2125.1997.t01-1-00574.x","article-title":"Non-linear pharmacokinetics of high-dose intraveneous verapamil","volume":"44","author":"Toffoli","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.012_b0235","first-page":"138","article-title":"Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug","volume":"18","author":"Vickers","year":"1989","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0240","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.20131","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride and atenolol","volume":"93","author":"Vogelpoel","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.012_b0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2013.07.012_b0250","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental transit and dispersion model analysis of small intestinal transit flow in humans","volume":"140","author":"Yu","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2013.07.012_b0255","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1124\/dmd.109.026658","article-title":"Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolites","volume":"37","author":"Zhang","year":"2009","journal-title":"Drug Metab. Dispos."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T07:21:56Z","timestamp":1539501716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":51,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0928098713002996"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.07.012","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}